UK markets open in 1 hour 40 minutes
NIKKEI 225
38,642.16 +9.14 (+0.02%) HANG SENG
17,994.25 -341.07 (-1.86%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,376.30 +7.30 (+0.31%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
50,948.59 -598.55 (-1.16%)
Amgen Inc. (4AMGN.TI)
TLO - TLO Delayed price. Currency in EUR
Add to watchlist
At close: 03:33PM CEST
| Previous close | 285.10 |
| Open | 249.95 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 249.95 - 284.55 |
| 52-week range | 200.20 - 284.55 |
| Volume | |
| Avg. volume | 53 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksHere is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ZacksAmgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-ALL in the consolidation phase, regardless of MRD status.
PR NewswireFDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.
© 2024 Yahoo. All rights reserved.